<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-topic" /><meta name="keywords" content="Myocardial infarction: ST-segment elevation; Oxygen: myocardial infarction; Aspirin: myocardial infarction; Heparin: myocardial infarction; Nitrates: myocardial infarction; Beta-adrenoceptor blocking drugs: myocardial infarction; ACE inhibitors: myocardial infarction" /><meta name="IX" content="Myocardial infarction: ST-segment elevation; Oxygen: myocardial infarction; Aspirin: myocardial infarction; Heparin: myocardial infarction; Nitrates: myocardial infarction; Beta-adrenoceptor blocking drugs: myocardial infarction; ACE inhibitors: myocardial infarction" /><title>Management of ST-segment elevation myocardial infarction (STEMI): British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="PHP1566-management-of-st-segment-elevation-myocardial-infarction-stemi.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="PHP1566-management-of-st-segment-elevation-myocardial-infarction-stemi.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=PHP1566-management-of-st-segment-elevation-myocardial-infarction-stemi.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP747-cardiovascular-system.htm">2 Cardiovascular system</a> &gt; <a href="PHP1559-stable-angina-acute-coronary-syndromes-and-fibrinolysis.htm">2.10 Stable angina, acute coronary syndromes, and fibrinolysis</a> &gt; <a href="PHP1560-management-of-stable-angina-and-acute-coronary-syndromes.htm">2.10.1 Management of stable angina and acute coronary syndromes</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="PHP1564-management-of-unstable-angina-and-non-st-segment-elevation-myocardial-infarction-nstemi.htm" title="Previous: Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI)">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="PHP1569-fibrinolytic-drugs.htm" title="Next: 2.10.2 Fibrinolytic drugs">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Management of ST-segment elevation myocardial infarction (STEMI)</h1><?highlighter on?><div id="pC" class="jN"><div class="cI"><p>Local guidelines for the management of myocardial infarction should be followed where they exist</p></div><p id="PHP1567">These notes give an overview of the initial and long-term management of myocardial infarction with ST-segment elevation (STEMI). For advice on the management of non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina, see <a title="BNF:topic: Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI)" href="PHP1564-management-of-unstable-angina-and-non-st-segment-elevation-myocardial-infarction-nstemi.htm">above</a>. The aims of management of STEMI are to provide supportive care and pain relief, to promote reperfusion and to reduce mortality. Oxygen, nitrates, and diamorphine or morphine can provide initial support and pain relief; aspirin and percutaneous coronary intervention or thrombolytics promote reperfusion; anticoagulants help to reduce re-occlusion and systemic embolisation; long-term use of aspirin, beta-blockers, ACE inhibitors, and statins help to reduce mortality further.</p> <div><h2>Initial management</h2><p><strong>Oxygen</strong> (<a title=" Oxygen" href="PHP2009-oxygen.htm">section 3.6</a>) should be administered if there is evidence of hypoxia, pulmonary oedema, or continuing myocardial ischaemia; hyperoxia should be avoided and particular care is required in patients with chronic obstructive airways disease.</p><p>The pain (and anxiety) of myocardial infarction is managed with slow intravenous injection of <strong>diamorphine</strong> or <strong>morphine</strong> (<a title=" Opioid analgesics" href="PHP2667-opioid-analgesics.htm">section 4.7.2</a>); an antiemetic such as metoclopramide (or, if left ventricular function is not compromised, cyclizine) by intravenous injection should also be given (<a title=" Drugs used in nausea and vertigo" href="PHP2505-drugs-used-in-nausea-and-vertigo.htm">section 4.6</a>).</p><p><strong>Aspirin</strong> (chewed or dispersed in water) is given for its antiplatelet effect (<a title=" Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>); a dose of 300 mg is suitable. If aspirin is given before arrival at hospital, a note saying that it has been given should be sent with the patient. <strong>Clopidogrel</strong>, in a dose of 300 mg (or 600 mg [unlicensed] if used prior to percutaneous coronary intervention), should also be given (<a title="section: Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>). <strong>Prasugrel</strong>, in a dose of 60 mg, is an alternative to clopidogrel in certain patients undergoing percutaneous coronary intervention (see <a title="BNF:target-block: nice prasugrel 2009" href="PHP1519-antiplatelet-drugs.htm#PHP1521">NICE guidance</a>). <strong>Ticagrelor</strong>, in a dose of 180 mg, is also an alternative to clopidogrel (see <a title="BNF:target-block: Ticagrelor NICE guidance" href="PHP1519-antiplatelet-drugs.htm#PHP1522">NICE guidance</a>).</p><p>Patency of the occluded artery can be restored by percutaneous coronary intervention or by giving a <strong>thrombolytic drug</strong> (<a title=" Fibrinolytic drugs" href="PHP1569-fibrinolytic-drugs.htm">section 2.10.2</a>), unless contra-indicated. Percutaneous coronary intervention is the preferred method; a <strong>glycoprotein IIb/IIIa inhibitor</strong> (<a title="section: Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>) can be used to reduce the risk of immediate vascular occlusion in intermediate- and high-risk patients. Patients undergoing percutaneous coronary intervention should also receive either unfractionated heparin or a low molecular weight heparin (e.g. enoxaparin); <strong>bivalirudin</strong> (<a title="BNF:monograph: BIVALIRUDIN" href="PHP1471-bivalirudin.htm">section 2.8.1</a>) is an alternative to the combination of a glycoprotein IIb/IIIa inhibitor plus a heparin (see also <a title="BNF:target-block: Bivalirudin NICE guidance" href="PHP1469-hirudins.htm#PHP1470">NICE guidance</a>). In patients who cannot be offered percutaneous coronary intervention within 90 minutes of diagnosis, a thrombolytic drug should be administered along with either unfractionated heparin (for maximum 2 days), a low molecular weight heparin (e.g. enoxaparin), or fondaparinux. See <a title="BNF:target-block: Antiplatelet drugs in coronary stenting" href="PHP1519-antiplatelet-drugs.htm#PHP1523">section 2.9</a> for the use of antiplatelet drugs in patients undergoing coronary stenting.</p><p>Patients who do not receive reperfusion therapy (with percutaneous coronary intervention or a thrombolytic) should be treated with either fondaparinux, enoxaparin, or unfractionated heparin. Prescribers should consult product literature and local protocols (where they exist) for details of anticoagulant dose and duration.</p><p><strong>Nitrates</strong> (<a title=" Nitrates" href="PHP1256-nitrates.htm">section 2.6.1</a>) are used to relieve ischaemic pain. If sublingual glyceryl trinitrate is not effective, intravenous glyceryl trinitrate or isosorbide dinitrate is given.</p><p>Early administration of some <strong>beta-blockers</strong> (<a title=" Beta-adrenoceptor blocking drugs" href="PHP934-beta-adrenoceptor-blocking-drugs.htm">section 2.4</a>) has been shown to be of benefit and should be given to patients without contra-indications.</p><p><strong>ACE inhibitors</strong> (<a title=" Angiotensin-converting enzyme inhibitors" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm">section 2.5.5.1</a>), and angiotensin-II receptor antagonists (<a title="sub-sub-section: Angiotensin-II receptor antagonists" href="PHP1205-angiotensin-ii-receptor-antagonists.htm">section 2.5.5.2</a>) if an ACE inhibitor cannot be used, are also of benefit to patients who have no contra-indications; in hypertensive and normotensive patients treatment with an ACE inhibitor, or an angiotensin-II receptor antagonist, can be started within 24 hours of the myocardial infarction and continued for at least 5–6 weeks (see below for long-term treatment).</p><p>All patients should be closely monitored for hyperglycaemia; those with diabetes or raised blood-glucose concentration should receive <strong>insulin</strong>.</p></div> <div id="PHP1568"><h2>Long-term management</h2><p>Long-term management following STEMI involves the use of several drugs which should ideally be started before the patient is discharged from hospital.</p><p><strong>Aspirin</strong> (<a title=" Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>) should be given to all patients, unless contra-indicated, at a dose of 75 mg daily. The addition of <strong>clopidogrel</strong> (<a title=" Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>) has been shown to reduce morbidity and mortality. Prasugrel or ticagrelor are alternatives to clopidogrel in certain patients (see <a title="BNF:section: Antiplatelet drugs" href="PHP1519-antiplatelet-drugs.htm">section 2.9</a>). For those intolerant of clopidogrel, and who are at low risk of bleeding, the combination of <strong>warfarin</strong> (<a title="sub-section: Oral anticoagulants" href="PHP1484-oral-anticoagulants.htm">section 2.8.2</a>) and aspirin should be considered. In those intolerant of both aspirin and clopidogrel, warfarin alone can be used. Warfarin should be continued for those who are already being treated for another indication, such as atrial fibrillation, with the addition of aspirin if there is a low risk of bleeding (see also <a title="BNF:target-block: Combined anticoagulant and antiplatelet therapy" href="PHP1485-coumarins-and-phenindione.htm#PHP1489">section 2.8.2</a>). The combination of aspirin with clopidogrel or warfarin increases the risk of bleeding. See <a title="BNF:target-block: Antiplatelet drugs in coronary stenting" href="PHP1519-antiplatelet-drugs.htm#PHP1523">section 2.9</a> for details of antiplatelet drug duration following coronary stenting.</p><p><strong>Beta-blockers</strong> (<a title=" Beta-adrenoceptor blocking drugs" href="PHP934-beta-adrenoceptor-blocking-drugs.htm">section 2.4</a>) should be given to all patients in whom they are not contra-indicated. Acebutolol, metoprolol, propranolol, and timolol are suitable; for patients with left ventricular dysfunction, carvedilol, bisoprolol, or long-acting metoprolol may be appropriate (<a title="sub-section: Drugs affecting the renin-angiotensin system" href="PHP1122-drugs-affecting-the-renin-angiotensin-system.htm">section 2.5.5</a>).</p><p><strong>Diltiazem</strong> [unlicensed] or <strong>verapamil</strong> (<a title=" Calcium-channel blockers" href="PHP1309-calcium-channel-blockers.htm">section 2.6.2</a>) can be considered if a beta-blocker cannot be used; however, they are contra-indicated in those with left ventricular dysfunction. Other calcium-channel blockers have no place in routine long-term management after a myocardial infarction.</p><p>An <strong>ACE inhibitor</strong> (<a title=" Angiotensin-converting enzyme inhibitors" href="PHP1124-angiotensin-converting-enzyme-inhibitors.htm">section 2.5.5.1</a>) should be considered for all patients, especially those with evidence of left ventricular dysfunction. If an ACE inhibitor cannot be used, an angiotensin-II receptor antagonist may be used for patients with heart failure. A relatively high dose of either the ACE inhibitor or angiotensin-II receptor antagonist may be required to produce benefit.</p><p><strong>Nitrates</strong> (<a title=" Nitrates" href="PHP1256-nitrates.htm">section 2.6.1</a>) are used for patients with angina.</p><p><strong>Eplerenone</strong> (<a title="monograph-family: Aldosterone antagonists" href="PHP830-aldosterone-antagonists.htm">section 2.2.3</a>) is licensed for use following a myocardial infarction in those with left ventricular dysfunction and evidence of heart failure.</p><p>For the role of <strong>statins</strong> in preventing recurrent cardiovascular events, see <a title=" Lipid-regulating drugs" href="PHP1621-lipid-regulating-drugs.htm">section 2.12</a>.</p></div> </div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="PHP1564-management-of-unstable-angina-and-non-st-segment-elevation-myocardial-infarction-nstemi.htm">Previous: Management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI)</a> | <a class="top" href="PHP1566-management-of-st-segment-elevation-myocardial-infarction-stemi.htm#">Top</a> | <a accesskey="]" href="PHP1569-fibrinolytic-drugs.htm">Next: 2.10.2 Fibrinolytic drugs</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>